相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins
Samuel E. DePrimo et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Hypertension as a predictive factor of Sunitinib activity
O. Rixe et al.
ANNALS OF ONCOLOGY (2007)
We should desist using RECIST, at least in GIST
Robert S. Benjamin et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Epidemiologic aspects of renal cell carcinoma
Joseph K. McLaughlin et al.
SEMINARS IN ONCOLOGY (2006)
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma
RJ Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
S Faivre et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor
A Bex et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Searching for the hereditary causes of renal-cell carcinoma
CP Pavlovich et al.
NATURE REVIEWS CANCER (2004)
Rhebbing up mTOR - New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis
DJ Kwiatkowski
CANCER BIOLOGY & THERAPY (2003)
Clinical translation of angiogenesis inhibitors
R Kerbel et al.
NATURE REVIEWS CANCER (2002)
Structural basis for the recognition of hydroxyproline in αIF-1α by pVHL
WC Hon et al.
NATURE (2002)
Clinical trial designs for cytostatic agents: Are new approaches needed?
EL Korn et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
